Molecular and clinical implications of CHD1 loss and SPOP mutations in advanced prostate cancer.

被引：1
|
作者：
Rescigno, Pasquale
Boysen, Gunther
Rodrigues, Daniel Nava
Seed, George
Dolling, David
Riisnaes, Ruth
Crespo, Mateus
Bianchini, Diletta
Sumanasuriya, Semini
Figueiredo, Ines
Christova, Rossitza
Gil, Veronica
Goodall, Jane
Sharp, Adam
Rubin, Mark A.
Yuan, Wei
Barbieri, Christopher
Mateo, Joaquin
Carreira, Suzanne
De Bono, Johann S.
机构：
[1] Inst Canc Res, Sutton, Surrey, England
[2] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England
[3] Inst Canc Res, Clin Trials & Stat Unit, London, England
[4] Univ Bern, Bern, Switzerland
[5] Weill Cornell Med Coll, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.5064
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5064
引用
收藏
页数：1
相关论文
共 50 条
  • [21] CHD1 Deletion in a Cohort of Castration-Resistant Prostate Cancer
    Friedman, C. S.
    Deng, F-M
    Barbieri, C. E.
    MacDonald, T.
    Xu, W.
    Melamed, J.
    Rubin, M. A.
    Mosquera, J. M.
    Zhou, M.
    MODERN PATHOLOGY, 2014, 27 : 230A - 230A
  • [22] CHD1 Deletion in a Cohort of Castration-Resistant Prostate Cancer
    Friedman, C. S.
    Deng, F-M
    Barbieri, C. E.
    MacDonald, T.
    Xu, W.
    Melamed, J.
    Rubin, M. A.
    Mosquera, J. M.
    Zhou, M.
    LABORATORY INVESTIGATION, 2014, 94 : 230A - 230A
  • [23] RECURRENT MUTATIONS IN SPOP DEFINE A DISTINCT MOLECULAR CLASS OF PROSTATE CANCER
    Barbieri, Christopher
    Baca, Sylvan
    Demichelis, Francesca
    Lawrence, Michael
    Blattner, Mija
    Theurillat, Jean-Philippe
    Boysen, Gunther
    Stojanov, Petar
    Van Allen, Eli
    Stransky, Nico
    Nickerson, Elizabeth
    Park, Kyung
    Kitabayashi, Naoki
    MacDonald, Theresa
    Terry Vuong
    Auclair, Daniel
    Onofrio, Robert
    Guiducci, Candace
    Cibulskis, Kristian
    Sivachenko, Andrey
    Carter, Scott
    Ambrogio, Lauren
    Parkin, Melissa
    White, Thomas
    Saksena, Gordon
    Voet, Douglas
    Ramos, Alex H.
    Winckler, Wendy
    Hussain, Wasay
    Wilkinson, Jane
    Ardlie, Kristin
    Banerjee, Samprit
    Baldwin, Jennifer
    Mosquera, Juan Miguel
    Gabriel, Stacey B.
    Kantoff, Philip W.
    Golub, Todd R.
    Meyerson, Matthew
    Lander, Eric S.
    Getz, Gad
    Nelson, Peter
    Garraway, Levi A.
    Tewari, Ashutosh
    Rubin, Mark A.
    JOURNAL OF UROLOGY, 2012, 187 (04): : E532 - E533
  • [24] Recurrent inactivating mutations in SPOP define a molecular subset of prostate cancer
    Barbieri, Christopher E.
    Demichelis, Francesca
    Grasso, Catherine
    Terry Vuong
    MacDonald, Theresa
    Boysen, Gunther
    Banerjee, Samprit
    Kitabayashi, Naoki
    Berger, Michael F.
    Tewari, Ashutosh K.
    Garraway, Levi A.
    Chinnaiyan, Arul M.
    Rubin, Mark A.
    CANCER RESEARCH, 2011, 71
  • [25] CHD1-loss promotes tumor heterogeneity and therapy resistance in prostate cancer.
    Zhang, Zeda
    Zhou, Chuanli
    Li, Xiaoling
    Sawyers, Charles
    Mu, Ping
    CANCER RESEARCH, 2020, 80 (21)
  • [26] CHD1 as regulator of cell adhesion in Ets fusion negative prostate cancer
    Kareddula, Aparna
    Petrosky, Whitney
    Tereshchenko, Irina
    Medina, Daniel
    Aviv, Hana
    Singer, Eric
    DiPaola, Robert S.
    Hirshfield, Kim M.
    CANCER RESEARCH, 2017, 77
  • [27] Rearrangement of ERG and CHD1 genes in prostate cancer as a marker of tumor heterogeneity
    Tereshchenko, Irina V.
    Zhong, Hua
    Chekmareva, Marina
    Santanam, Urmila
    Petrosky, Whitney
    Kane-Goldsmith, Noriko
    Tischfield, Jay A.
    DiPaola, Robert
    CANCER RESEARCH, 2014, 74 (19)
  • [28] The role of chromatin remodeler CHD1 in genomic alterations and prostate cancer progression
    Liu, Wennuan
    Rodrigues, Lindsey Ulkus
    Li, Tao
    Zhang, Zheng
    Rider, Leah
    Romero, Lina
    Zheng, Lilly S.
    Isaacs, William B.
    Cramer, Scott
    Xu, Jianfeng
    CANCER RESEARCH, 2015, 75 (22)
  • [29] ALTERATION OF METASTATIC BEHAVIOR BY SHRNA MEDIATED KNOCKDOWN (KD) OF CHD1 IN HUMAN PROSTATE XENOGRAFT TUMORS AND CLINICAL OUTCOME OF PATIENTS WITH CHD1 DELETION
    Oh, Su Jung
    Tilki, Derya
    Matuszcak, Christiane
    Tennstedt, Pierre
    Baumgart, Simon
    Johnsen, Steven A.
    Sirma, Hueseyin
    Simon, Ronald
    Lange, Tobias
    JOURNAL OF UROLOGY, 2017, 197 (04): : E338 - E338
  • [30] CHD1: a new treatment biomarker for recombination deficiency in castration resistant prostate cancer?
    Helleday, T.
    ANNALS OF ONCOLOGY, 2017, 28 (07) : 1407 - 1408
12345